Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial
Michel Seymour(University of Leeds), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Angela Meade(Medical Research Council), Harpreet Wasan(Hammersmith Hospital), Tim Maughan(University of Liverpool), A. Brewster(Velindre NHS Trust), Brandon May(Cheltenham General Hospital), S.F. Shepherd(Cheltenham General Hospital), M.S. O'Mahoney(Cheltenham General Hospital)
Cited by 44
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k